Biotherapy in juvenile idiopathic arthritis Moroccan patients: a single center experience

Bouayed, K.; Hamraoui, D.; Mikou, N.; Sakhi, Asmaa; Hilmi, Wassim

doi:10.11604/pamj.2022.41.135.27377

Cited by 3 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cases characterized by persistent active disease may lead to damage to articular cartilage and underlying bone [ 5 , 7 , 8 ]. Over the last decade, several advancements pertaining to the pathogenesis of JIA have led to the emergence of biological disease-modifying antirheumatic drugs, significantly improving disease outcomes [ 9 , 10 , 11 ]. Prompt diagnosis and therapeutic interventions are considered overarching principles in disease management [ 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

Examining the Relationship between Systemic Immune–Inflammation Index and Disease Severity in Juvenile Idiopathic Arthritis

Nicoară,

Munteanu,

Scutca

et al. 2024

Cells

View full text Add to dashboard Cite

Juvenile Idiopathic Arthritis (JIA), the leading childhood rheumatic condition, has a chronic course in which persistent disease activity leads to long-term consequences. In the era of biologic therapy and tailored treatment, precise disease activity assessment and aggressive intervention for high disease activity are crucial for improved outcomes. As inflammation is a fundamental aspect of JIA, evaluating it reflects disease severity. Recently, there has been growing interest in investigating cellular immune inflammation indices such as the neutrophil-to-lymphocyte ratio (NLR) and systemic immune inflammation index (SII) as measures of disease severity. The aim of this retrospective study was to explore the potential of the SII in reflecting both inflammation and disease severity in children with JIA. The study comprised 74 JIA patients and 50 healthy controls. The results reveal a notable increase in median SII values corresponding to disease severity, exhibiting strong correlations with traditional inflammatory markers, including CRP and ESR (ρ = 0.714, ρ = 0.661), as well as the JADAS10 score (ρ = 0.690). Multiple regression analysis revealed the SII to be independently associated with JADAS10. Furthermore, the SII accurately distinguished patients with high disease activity from other severity groups (AUC = 0.827, sensitivity 81.5%, specificity 66%). These findings suggest that integrating the SII as an additional measure holds potential for assessing disease activity in JIA.

show abstract

Section: Introductionmentioning

confidence: 99%

Examining the Relationship between Systemic Immune–Inflammation Index and Disease Severity in Juvenile Idiopathic Arthritis

Nicoară,

Munteanu,

Scutca

et al. 2024

Cells

View full text Add to dashboard Cite

show abstract

“…One of the most effective and studied GEBDs today is anti-TNF drugs, which include etanercept, adalimumab, infl iximab, certolizumab-pegol, and golimumab (19). Their clinical effi cacy has repeatedly been investigated, as a result of which they were recognised as the most effective drugs for the treatment of JIA (20)(21)(22)(23)(24). However, more modern drugs are interleukin 1 blockers (anakinra) and interleukin 6 (tocilizumab), the effi cacy of which still needs to be investigated, considering the complex pathophysiology of various forms of JIA.…”

Section: Introductionmentioning

confidence: 99%

Experience of using genetically engineered biological drugs in children with a systemic form of JIA in the Karaganda region

KENZHETAEVA,

KENZHETAYEVA,

MELDEBEKOVA

et al. 2023

BLL

View full text Add to dashboard Cite

Despite all the achievements of science and medicine, juvenile idiopathic arthritis today remains one of the main childhood diseases that lead to severe irreversible consequences. This, in turn, makes it urgent to search for effective drugs for the treatment of juvenile idiopathic arthritis, of which interleukin 1 (anakinra) and interleukin 6 (tocilizumab) inhibitors are becoming increasingly popular. AIM: to analyse the effi cacy of genetically engineered biological drugs, namely anakinra and tocilizumab in children with systemic juvenile idiopathic arthritis among patients of the Karaganda region. The study involved 176 patients aged 4-17 years with a diagnosis of systemic juvenile idiopathic arthritis and with resistance to methotrexate for 3 months. Among all patients, 64 children received injections of anakinra, and 63 received tocilizumab in standard doses. The control group consisted of 50 patients of the same age category. Assessment of the effi cacy of treatment was conducted at 2, 4, 8, 16, 24, and 48 weeks using ACR Pediatric criteria. The clinical effect of both drugs was detected as early as the second week after the start of therapy. At week 12 of the study in the tocilizumab group, the effi cacy of treatment for ACR Pediatric 30, 50, and 70 reached 82 %, 71 %, and 69 %, and in the anakinra group -89 %, 81 %, and 80 % respectively, while in the control group ACR Pediatric 30 after 12 weeks of treatment was achieved in 21 % of patients, ACR Pediatric 50 -in 12 %, and ACR Pediatric 70 -in 9 % (p < 0.001). By the end of the extended open phase, after 48 weeks of the study among patients treated with tocilizumab, the number of patients who reached ACR Pediatric 70 was 85 %. Those who reached ACR Pediatric 90 were 55 %, whereas, in the anakinra group, 89 % reached ACR Pediatric 70 and 61 % -ACR Pediatric 90. Moreover, the clinical effect was accompanied by an improvement in blood parameters, for example, haemoglobin and pro-infl ammatory markers (C-reactive protein, procalcitonin), which indicates the role of interleukin 1 and interleukin 6 in the aetiology of anaemia in juvenile idiopathic arthritis. The use of tocilizumab and anakinra as treatment for systemic juvenile idiopathic arthritis resistant to methotrexate leads to a stable improvement in the general condition of patients (Ref. 36).

show abstract

Anakinra

2022

Reactions Weekly

View full text Add to dashboard Cite

Biotherapy in juvenile idiopathic arthritis Moroccan patients: a single center experience

Cited by 3 publications

References 29 publications

Examining the Relationship between Systemic Immune–Inflammation Index and Disease Severity in Juvenile Idiopathic Arthritis

Examining the Relationship between Systemic Immune–Inflammation Index and Disease Severity in Juvenile Idiopathic Arthritis

Experience of using genetically engineered biological drugs in children with a systemic form of JIA in the Karaganda region

Anakinra

Contact Info

Product

Resources

About